Find Savolitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Volitinib, 1313725-88-0, Azd-6094, Hmpl-504, Azd6094, Savolitinib [inn]
Molecular Formula
C17H15N9
Molecular Weight
345.4  g/mol
InChI Key
XYDNMOZJKOGZLS-NSHDSACASA-N
FDA UNII
2A2DA6857R

Savolitinib
Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.
1 2D Structure

Savolitinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
2.1.2 InChI
InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
2.1.3 InChI Key
XYDNMOZJKOGZLS-NSHDSACASA-N
2.1.4 Canonical SMILES
CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
2.1.5 Isomeric SMILES
C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
2.2 Other Identifiers
2.2.1 UNII
2A2DA6857R
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)triazolo(4,5-b)pyrazine

2. Azd6094

3. Hmpl-504

4. Volitinib

2.3.2 Depositor-Supplied Synonyms

1. Volitinib

2. 1313725-88-0

3. Azd-6094

4. Hmpl-504

5. Azd6094

6. Savolitinib [inn]

7. Hmpl504

8. (s)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-[1,2,3]triazolo[4,5-b]pyrazine

9. Chembl3334567

10. 2a2da6857r

11. 1h-1,2,3-triazolo(4,5-b)pyrazine, 1-((1s)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1h-pyrazol-4-yl)-

12. 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine

13. Orpathys

14. Unii-2a2da6857r

15. Azd6094, Hmpl-504

16. Volitinib(savolitinib)

17. Azd-6094volitinib

18. Savolitinib (usan/inn)

19. Savolitinib [usan:inn]

20. Savolitinib [usan]

21. Savolitinib [who-dd]

22. Gtpl9918

23. Hmpl 504

24. Schembl12489208

25. Ex-a845

26. Dtxsid801111016

27. Azd 6094

28. Bdbm50023342

29. Mfcd28359096

30. Nsc782121

31. Nsc800966

32. S7674

33. Akos030526403

34. Savolitinib(azd6094, Hmpl-504)

35. Zinc149738712

36. Ccg-267976

37. Db12048

38. Nsc-782121

39. Nsc-800966

40. Compound 28 [pmid: 25148209]

41. Ncgc00475727-01

42. Ac-35267

43. As-35250

44. Bv160378

45. Hy-15959

46. Savolitinib;volitinib;hmpl-504;azd-6094

47. A14419

48. D11139

49. J-690125

50. Q27254463

51. (3e)-5-chloro-3-[(5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}-2-furyl)methylene]-1,3-dihydro-2h-indol-2-one Hydrochloride

52. 1-((s)-1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)-triazolo(4,5-b)pyrazine

53. 4-{1-[(1s)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1h-pyrazole

2.4 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 345.4 g/mol
Molecular Formula C17H15N9
XLogP31.5
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count3
Exact Mass345.14504152 g/mol
Monoisotopic Mass345.14504152 g/mol
Topological Polar Surface Area91.6 Ų
Heavy Atom Count26
Formal Charge0
Complexity505
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of lung cancer


Treatment of renal neoplasms


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty